SCHEMBL1015931

SCHEMBL1015931

Cn1cc(-n2ncc3c2CCN(CC(=O)N2CCN(C4CCC4)CC2)C3)ccc1=O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
KCNJ1 P48048 1/20 0.37
HPGDS O60760 3/20 0.37
PARP1 P09874 1/20 0.37
PLA2G7 Q13093 1/20 0.36
PDK2 Q15119 3/20 0.35
P2RY12 Q9H244 1/20 0.35
HRH3 Q9Y5N1 4/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
ENPP2 Q13822 1/20 0.34
SPR P35270 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14420841 0.90 PARP1 (0.37) KCNJ1HPGDSPARP1PLA2G7PDK2
SCHEMBL1018081 0.85 HRH3 (0.39) HPGDSPARP1PDK2P2RY12HRH3
SCHEMBL1016572 0.85 HRH3 (0.42) HPGDSPARP1PDK2P2RY12HRH3
SCHEMBL1017334 0.85 PDK2 (0.48) HPGDSPLA2G7PDK2HRH3MEN1
SCHEMBL1017564 0.84 HRH3 (0.39) TLR4TLR9TLR8TLR7PARP1
SCHEMBL1020634 0.83 HRH3 (0.38) HPGDSPARP1PDK2HRH3MEN1
SCHEMBL1019845 0.82 HRH3 (0.45) KCNJ1HPGDSPDK2HRH3MEN1
SCHEMBL14420817 0.81 HPGDS (0.38) HPGDSPARP1PDK2P2RY12HRH3
SCHEMBL1017186 0.81 HRH3 (0.37) HPGDSPARP1HRH3MEN1KMT2A
SCHEMBL1017368 0.80 HRH3 (0.38) HPGDSPARP1PLA2G7HRH3SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 TLR4 654/4885TLR9 1174/4885TLR8 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.